Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts ’ recommendations
ConclusionAvelumab showed robust efficacy and a safety profile consistent with global EAP data. Results are aimed to improve current knowledge about mMCC treatment and access to immunooncologic strategies for treating LATAM patients.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Immunotherapy | Merkel Cell Carcinoma